Top 5 Drug Type | Count |
---|---|
Proteolysis-targeting chimeras (PROTAC) | 40 |
Small molecule drug | 15 |
Chemical drugs | 3 |
Herbal medicine | 2 |
Polymer | 1 |
Target |
Mechanism α5β1 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date25 Jul 2006 |
Mechanism BK channel agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1993 |
Target |
Mechanism CNDP1 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Aug 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Kakonein ( BK channel x L-type calcium channel x p53 ) | Reperfusion Injury More | Preclinical |
GDC-19 ( GPX4 ) | Neoplasms More | Preclinical |
STAT3 inhibitors(Zhejiang Chinese Medical University) ( STAT3 ) | Triple Negative Breast Cancer More | Preclinical |
GDC-21 ( GPX4 ) | Neoplasms More | Preclinical |
GDC-7 ( GPX4 ) | Neoplasms More | Preclinical |